(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Interpreter Starts Sobbing as 11-Year-Old Testifies About Last Time He Saw His Mom Before She Was Killed in Missile Strike - 2Unusual 'ingredients' helped stars form in a galaxy near the Milky Way
- 3Geminid shooting stars: One of 2025's most exciting meteor showers begins tonight
- 4Most loved Fish Dish: What's Your Sea Pleasure?
- 58 Fundamental Stages: Novice's Manual for Secure Your Android with a VPN
- They want better health care — so they're turning to crypto startups
- The most effective method to Help a Friend or family member Determined to have Cellular breakdown in the lungs
- Which European countries have mandatory or voluntary military service
- In the background: Visiting Notable Film Areas All over the Planet
- The most effective method to Beat Dental Tension and Guarantee Customary Exams
- Finding the Universe of Computer generated Reality: Individual Encounters
- Is Trump going to war with Venezuela?
- How will the universe end?
- The Rhythms of the Street: Shipping's Tune in the Economy's Symphony
